Subscribe to MDT Magazine News

Halozyme 4Q loss widens on revenue dip

March 11, 2011 12:45 pm | by The Associated Press | Comments

Biotechnology company Halozyme Therapeutics Inc. on Friday reported a wider fourth-quarter loss due to lower revenue and higher costs.The developer of enzyme-focused products, said it lost $16.9 million, or 17 cents per share, in the last three months of 2010, compared with a loss of $12.7...

Gilead tells shareholders to reject tender offer

March 11, 2011 12:45 pm | by The Associated Press | Comments

Drug maker Gilead Sciences Inc. on Friday recommended shareholders reject an unsolicited "mini-tender" offer by TRC Capital Corp. to buy up to 3 million shares, or less than 1 percent, of the company's common stock.TRC is offering to buy the stock at $37.25 per share, which is 4.6 percent less than...

Inhibitex 4Q loss widens on costs

March 11, 2011 11:45 am | by The Associated Press | Comments

Biotechnology company Inhibitex Inc. reported a wider fourth-quarter loss Friday, as it continued developing a potential treatment for shingles and a potential drug for hepatitis C.Inhibitex reported a net loss of $7 million, or 11 cents per share, for the three months ended Dec. 31 compared...


Ferring Pharmaceuticals, Inc. Congratulates R & B and Pop Icon Gloria Gaynor, Named 'Woman of the Year' by Arthritis Foundation

March 11, 2011 11:36 am | by Bio-Medicine.Org | Comments

PARSIPPANY, N.J., March 11, 2011 /- Ferring Pharmaceuticals Inc. congratulates GRAMMY® award-winning recording artist Gloria Gaynor, who will receive the inaugural Woman of the Year award from the Arthritis Foundation's New York Chapter.  As part of the Foundation's arthritis...


Sirona Dental prices secondary offering of shares

March 11, 2011 9:45 am | by The Associated Press | Comments

Sirona Dental Systems Inc. said Friday it priced an offering of nearly 5 million shares of stock at $48.85 per share, a 3 percent discount from its previous closing price.The Long Island City, N.Y., maker of dental equipment said the secondary offering involves 4.5 million shares sold by Sirona...

<i>Blog: </i>Discovering biotech startup Nimbus

March 11, 2011 9:37 am | by Mass High Tech: The Journal of New England Technology | Comments

Atlas Venture partner Bruce Booth blogs: We founded Nimbus Discovery in 2009 with Schrödinger and have incubated the company here at Atlas for the past couple years. It's fair to say Nimbus is a rather unconventional biotech, possessing three distinctive features.

Spencer Pharmaceutical signs deal with Univalor unit

March 11, 2011 9:37 am | by Mass High Tech: The Journal of New England Technology | Comments

Boston biotech Spencer Pharmaceutical Inc. has signed an agreement with Polyvalor LP, the commercial partner of Ecole Polytechnique de Montreal, to further develop the technologies protected by two patent applications developed by professor Michael Buschmann and co-workers at the Montreal...

Lantheus Medical lands SPA approval

March 11, 2011 9:37 am | by Mass High Tech: The Journal of New England Technology | Comments

The U.S. Food and Drug Administration has given Lantheus Medical Imaging Inc. a Special Protocol Assessment (SPA) approval for a Phase 3 clinical trial of an injection agent for diagnosing coronary artery disease.


Constitution Medical completes $20M offering

March 11, 2011 9:37 am | by Mass High Tech: The Journal of New England Technology | Comments

Constitution Medical Investors Inc. of Westborough has completed a $20 million equity offering with 10 investors, including corporate officers and partners at Warburg Pincus LLC, according to a filing with the U.S. Securities and Exchange Commission.

FDA eSubmitter (Radiation Safety Report Video Tutorial and Updated User Guide)

March 11, 2011 9:30 am | by U.S. Food & Drug Administration | Comments

The Food and Drug Administration?s eSubmitter tool is part of an electronic submissions program that originated in the Center for Devices and Radiological Health (CDRH). The eSubmitter program is the result of two successful pilot programs at CDRH named..


Researchers link novel biomarkers to asthma and COPD

March 11, 2011 8:35 am | by EurekAlert | Comments

(American Thoracic Society) Four novel biomarkers have been identified which may aid in the diagnosis and management of asthma and chronic obstructive pulmonary disease, according to a study conducted by researchers in Australia, who determined the biomarkers may be used in different...


'Microparticles' useful in identifying earliest signs of emphysema

March 11, 2011 8:35 am | by EurekAlert | Comments

(American Thoracic Society) Monitoring blood for tiny particles released by cells lining the lungs may help clinicians diagnose emphysema in its earliest stages, according to researchers from Weill Cornell Medical College. The particles, called endothelial microparticles, are shed during...


Moody's Upgrades Mylan

March 11, 2011 8:35 am | by Bio-Medicine.Org | Comments

PITTSBURGH, March 11, 2011 /- Mylan Inc. (Nasdaq: MYL ) today reported that Moody's Investors Service ("Moody's") has upgraded the company's credit ratings, including the "Corporate Family Rating," to Ba2 from Ba3 (positive outlook). Following this action, Moody's rating outlook is...


Contrary to popular belief, not all cases of chronic pancreatitis are alcohol-induced

March 11, 2011 5:36 am | by EurekAlert | Comments

(American Gastroenterological Association) The relative rate of alcohol-related chronic pancreatitis is lower when compared to other causes.


Tolerx and GlaxoSmithKline Announce Phase 3 Defend-1 Study of Otelixizumab in Type 1 Diabetes Did Not Meet Its Primary Endpoint

March 11, 2011 4:35 am | by Bio-Medicine.Org | Comments

CAMBRIDGE, Mass. and LONDON, March 11, 2011 /- Tolerx, Inc. and GlaxoSmithKline (GSK) today announced that the Phase 3 DEFEND-1 study of otelixizumab, an investigational humanized anti-CD3 monoclonal antibody, did not meet the primary efficacy endpoint of change in C-peptide at month 12...



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.